PT  - JOURNAL ARTICLE
AU  - Seth J. Zost
AU  - Pavlo Gilchuk
AU  - Rita E. Chen
AU  - James Brett Case
AU  - Joseph X. Reidy
AU  - Andrew Trivette
AU  - Rachel S. Nargi
AU  - Rachel E. Sutton
AU  - Naveenchandra Suryadevara
AU  - Elaine C. Chen
AU  - Elad Binshtein
AU  - Swathi Shrihari
AU  - Mario Ostrowski
AU  - Helen Y. Chu
AU  - Jonathan E. Didier
AU  - Keith W. MacRenaris
AU  - Taylor Jones
AU  - Samuel Day
AU  - Luke Myers
AU  - F. Eun-Hyung Lee
AU  - Doan C. Nguyen
AU  - Ignacio Sanz
AU  - David R. Martinez
AU  - Ralph S. Baric
AU  - Larissa B. Thackray
AU  - Michael S. Diamond
AU  - Robert H. Carnahan
AU  - James E. Crowe, Jr.
TI  - Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
AID  - 10.1101/2020.05.12.091462
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.05.12.091462
4099  - http://biorxiv.org/content/early/2020/05/13/2020.05.12.091462.short
4100  - http://biorxiv.org/content/early/2020/05/13/2020.05.12.091462.full
AB  - Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of new antibody discovery methodologies.Competing Interest StatementR.S.B. has served as a consultant for Takeda and Sanofi Pasteur on issues related to vaccines. M.S.D. is a consultant for Inbios Vir Biotechnology, NGM Biopharmaceuticals, Eli Lilly, and on the Scientific Advisory Board of Moderna, and a recipient of unrelated research grants from Moderna and Emergent BioSolutions. J.E.C. has served as a consultant for Sanofi and is on the Scientific Advisory Boards of CompuVax and Meissa Vaccines, is a recipient of previous unrelated research grants from Moderna and Sanofi and is Founder of IDBiologics, Inc. Vanderbilt University has applied for patents concerning SARS-CoV-2 antibodies that are related to this work. F.E.-H.L., D.C.N., and I.S. are inventors on a patent submitted for the plasmablast survival medium. J.D. and K.W.M. are employees of Berkeley Lights, Inc. All other authors declared no competing interests.